Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.900
-0.080 (-4.04%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
141.25M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IKT News
- 5 days ago - Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer - GlobeNewsWire
- 22 days ago - Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 7 weeks ago - Inhibikase Announces Expansion of Senior Leadership Team - GlobeNewsWire
- 2 months ago - Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study - Reuters
- 5 months ago - Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha
- 5 months ago - Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - GlobeNewsWire
- 6 months ago - Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - GlobeNewsWire